[{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Temple University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ Allergan","highestDevelopmentStatusID":"9","companyTruncated":"Temple University \/ Allergan"}]

Find Clinical Drug Pipeline Developments & Deals for Eluxadoline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 11, 2021

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 13, 2017

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          03

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 14, 2012

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          04

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 14, 2012

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          05

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2010

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Viberzi-Generic (eluxadoline) is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea.

                          Product Name : Viberzi-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Temple University

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Temple University

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 18, 2020

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Allergan

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University of North Carolina, Chapel Hill

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          University of North Carolina, Chapel Hill

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 05, 2018

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Allergan

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Allergan

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Allergan

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 22, 2018

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Allergan

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Allergan

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 09, 2016

                          Lead Product(s) : Eluxadoline

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank